Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Erythromycin ototoxicity: analysis and conclusions based on 22 case reports.

R C Haydon, J W Thelin, W E Davis

    Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery
    |December 1, 1984
    PubMed
    Summary

    Erythromycin can cause hearing loss in susceptible patients, especially with high doses. Risk factors include kidney/liver disease, older age, and female sex.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Facial Deformities.

    The American journal of dental science·2019
    Same author

    Overexpression of Ad5 precursor terminal protein accelerates recombinant adenovirus packaging and amplification in HEK-293 packaging cells.

    Gene therapy·2014
    Same author

    Muscle stiffness in down syndrome and other mentally handicapped subjects.

    Journal of motor behavior·2013
    Same author

    Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma.

    Oncogene·2011
    Same author

    New-onset systemic lupus erythematosus during chronic dialysis and after transplantation for idiopathic renal failure.

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
    Same author

    Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery.

    Gene therapy·2004

    Area of Science:

    • Ototoxicology
    • Pharmacology
    • Audiology

    Background:

    • Erythromycin is widely prescribed, but ototoxicity is a rare adverse effect.
    • Understanding risk factors for erythromycin-induced hearing loss is crucial for patient safety.

    Observation:

    • A review of 22 patients (20 from literature, 2 from case series) with erythromycin ototoxicity was conducted.
    • Patient data included age, sex, medical history, renal/hepatic function, erythromycin details (dose, duration, route), and auditory effects.

    Findings:

    • High-dose erythromycin (≥2 gm/day) combined with pre-existing renal/hepatic disease, advanced age, or female sex increases ototoxicity risk.
    • Auditory effects included varying onset, degree, and configuration of hearing loss, with potential for recovery.

    Related Experiment Videos

    Implications:

    • Clinicians should consider these risk factors when prescribing high-dose erythromycin.
    • Early recognition of auditory symptoms and patient counseling are vital for managing erythromycin ototoxicity.